Phaseline

Companies › Allist Pharmaceuticals

Allist Pharmaceuticals: clinical trials, targets and expected readouts

6 active drug programs in 31 registered trials: 13 Phase 2, 9 Phase 1, 8 Phase 3, 1 Phase 4; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Firmonertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Non-small Cell Lung Carcinoma; EGFR; NSCLC; Leptomeningeal Metastasis …Dec 2026
JAB-21822
KRAS G12C inhibitor
KRASPhase 3Advanced Non-squamous Non-small-cell Lung Cancer; KRAS P.G12C; Advanced Colorectal Cancer; NSCLC …Dec 2026
JAB-3312
SHP2 inhibitor
PTPN11Phase 3Advanced Non-squamous Non-small-cell Lung Cancer; KRAS P.G12CMar 2027
Furmonertinib Mesilate Tablets
EGFR tyrosine kinase inhibitor
EGFRPhase 3NSCLC Patients With Brain MetastasisMar 2029
Alflutinib Mesylate (AST2818)
EGFR tyrosine kinase inhibitor
EGFRPhase 3Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer–
AST2303 Tablets (ABK3376 Tablets)–Phase 1Locally Advanced or Metastatic Non-small Cell Lung CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03787992Alflutinib Mesylate (AST2818)Phase 3Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung CancerOncologySep 2021
NCT06838338JAB-21822Phase 1Colorectal CancerOncologyMar 2026
NCT06192849FirmonertinibPhase 2Non Small Cell Lung CancerOncologyDec 2026
NCT04853342FirmonertinibPhase 3Non-small Cell Lung CarcinomaOncologyDec 2026
NCT05466149FirmonertinibPhase 2NSCLCOncologyDec 2026
NCT06652048FirmonertinibPhase 2Non-Small Cell Lung CancerOncologyDec 2026
NCT05194995JAB-21822Phase 1Advanced Colorectal CancerOncologyDec 2026
NCT05009329JAB-21822Phase 1NSCLCOncologyDec 2026
NCT06955988AST2303 Tablets (ABK3376 Tablets)Phase 1Locally Advanced or Metastatic Non-small Cell Lung CancerOncologyDec 2026
NCT06674343FirmonertinibPhase 3Advanced or Metastatic Non-small Cell Lung CancerOncologyDec 2026
NCT06008288JAB-21822Phase 2KRAS P.G12COncologyDec 2026
NCT05288205JAB-21822Phase 1KRAS P.G12COncologyMar 2027
NCT05288205JAB-3312Phase 1KRAS P.G12COncologyMar 2027
NCT07087223FirmonertinibPhase 1Non Small Cell Lung Cancer NSCLCOncologyApr 2027
NCT07092202FirmonertinibPhase 4Leptomeningeal MetastasisOncologyMay 2027
NCT05276726JAB-21822Phase 1Non-small Cell Lung CancerOncologyAug 2027
NCT06945705FirmonertinibPhase 2NSCLCOncologySep 2027
NCT07655622FirmonertinibPhase 1Non-Small-Cell Lung CancerOncologyDec 2027
NCT06956001FirmonertinibPhase 3EGFROncologyDec 2027
NCT07548060FirmonertinibPhase 2NSCLC Stage IVOncologyJan 2028
NCT05334277FirmonertinibPhase 2Non-small Cell Lung CancerOncologyFeb 2028
NCT05987826FirmonertinibPhase 2Non-Small Cell Lung CancerOncologyAug 2028
NCT07010419FirmonertinibPhase 3NSCLCOncologyOct 2028
NCT07304739FirmonertinibPhase 2Non Small Cell Lung CancerOncologyDec 2028
NCT05503667FirmonertinibPhase 2Lung Adenocarcinoma Stage IIIOncologyDec 2028
NCT06970639Furmonertinib Mesilate TabletsPhase 3NSCLC Patients With Brain MetastasisOncologyMar 2029
NCT06416410JAB-21822Phase 3Advanced Non-squamous Non-small-cell Lung CancerOncologySep 2029
NCT06416410JAB-3312Phase 3Advanced Non-squamous Non-small-cell Lung CancerOncologySep 2029
NCT05430802FirmonertinibPhase 2Non-small Cell Lung CancerOncologyDec 2029
NCT07622706FirmonertinibPhase 2NSCLCOncologyDec 2029
NCT07314216FirmonertinibPhase 2NSCLC (Non-small Cell Lung Carcinoma)OncologyDec 2030

Targets

EGFR (3) KRAS (1) PTPN11 (1)

Companies with the same targets

Revolution Medicines AstraZeneca Shanghai Henlius Biotech Novartis Johnson & Johnson (Janssen) Amgen Dizal Pharmaceuticals Chia Tai Tianqing Pharmaceutical Group Betta Pharmaceuticals Jiangsu HengRui Medicine

Companies built like this

HUYABIO International Jiangsu Alphamab Biopharmaceuticals Rakuten Medical Genfleet Therapeutics (Shanghai) Nanjing Sanhome Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.